Beyond Profiling: Using ADMET Models to Guide Decisions
暂无分享,去创建一个
Matthew Segall | Chris Leeding | Olga Obrezanova | M. Segall | O. Obrezanova | E. Champness | C. Leeding | Edmund Champness
[1] L. Carlsen,et al. Reverse quantitative structure-activity relationship for modelling the sorption of esfenvalerate to dissolved organic matter. A multivariate approach. , 2002, Chemosphere.
[2] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[3] A. Krogh. What are artificial neural networks? , 2008, Nature Biotechnology.
[4] Gábor Csányi,et al. Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties , 2007, J. Chem. Inf. Model..
[5] C. Moyes,et al. 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. , 2001, Journal of medicinal chemistry.
[6] Bruno Boulanger,et al. Towards a new age of virtual ADME/TOX and multidimensional drug discovery , 2002, J. Comput. Aided Mol. Des..
[7] Klaus-Robert Müller,et al. Accurate Solubility Prediction with Error Bars for Electrolytes: A Machine Learning Approach , 2007, J. Chem. Inf. Model..
[8] Joelle M. R. Gola,et al. Focus on success: using a probabilistic approach to achieve an optimal balance of compound properties in drug discovery , 2006, Expert opinion on drug metabolism & toxicology.
[9] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[10] Matthew D. Segall,et al. Automatic QSAR modeling of ADME properties: blood–brain barrier penetration and aqueous solubility , 2008, J. Comput. Aided Mol. Des..
[11] Bernard F. Buxton,et al. Drug Design by Machine Learning: Support Vector Machines for Pharmaceutical Data Analysis , 2001, Comput. Chem..